Table 1.
Demographic and clinical characteristics (n = 18, paired pre- and on ART donors and n = 39 original pre-ART cohort).
| Clinical | Original cohorta | Substudy cohort |
|
|---|---|---|---|
| Pre-ART | On ART | ||
| Age, years (range) | 31.9 (25.3–35.8) | 32.5 (21.3–44.6) | 35.7 (24.8–47.5) |
| Sex, % male (n) | 89.7 (35) | 94.4 (17) | 94.4 (17) |
| Duration on ART (years) | NA | NA | 3.4 (2.9–3.7) |
| Alcohol intake, % (n) | |||
| Never or less than monthly | 43.6 (17) | 66.7 (12) | 72.2 (13) |
| Weekly-monthly | 56.4 (22) | 33.3 (6) | 26.3 (5) |
| Daily (or almost) | 0.0 (0) | 0.0 (0) | 0.0 (0) |
| Number of participants on each ARV | |||
| Emtricitabine (FTC) | NA | NA | 16 |
| Tenofovir (TFV) | NA | NA | 17 |
| Efavirenz (EFV) | NA | NA | 16 |
| Lamivudine (3TC) | NA | NA | 2 |
| Zidovudine (AZT) | NA | NA | 1 |
| Laboratory | |||
| CD4, cells/μL | 360 (221–462) | 362 (262–425) | 645 (425–813) |
| CD8 total, cells/μL | 965 (662–1334) | 1070 (822–1411) | 844 (653–1074) |
| CD4/CD8 ratio | 0.32 (0.19–0.39) | 0.73 (0.64–1.07) | |
| HIV RNA, log10copies/mL (range) | 4.9 (4.5–5.5) | 4.8 (4.3–6.2) | 1.3 (1.3–1.6) |
| HBV DNA, log10IU/mL (range) | 7.4 (2.6–8.1) | 4.9 (1.0–8.6) | 1.0 (1.0–2.3) |
| HBV DNA, HBeAg+ (range) | 7.8 (7.3–8.4) | 7.5 (2.3–8.6) | 1.0 (1.0–2.3) |
| HBV DNA, HBeAg− (range) | 2.1 (1.5–3.5) | 2.2 (1.0–3.8) | 1.0 (1.0–1.2) |
| HBeAg positive, % (n) | 64.1% (25) | 55.6 (10) | 27.8 (5) |
| qHBsAg, IU/mL | 6403 (1327–18797) | 3543 (503–11,569) | 2878 (578–15,199) |
| Total bilirubin, mg/dL | 0.7 (0.5–0.8) | 0.6 (0.4–0.8) | 0.5 (0.4–0.6) |
| Alanine Aminotransferase, ALT, U/L | 38 (27–62) | 31 (27–50) | 39 (27–46) |
| Aspartate Aminotransaminase, AST, U/L | 33 (26–46) | 31 (26–40) | 27 (19–32) |
| Alkaline phosphatase, ALP, U/L | 70 (61–78) | 70 (63–78) | 80 (68–88) |
| γ-glutamyl transferase, GGT, U/L | 32 (19–61) | 31 (17–51) | 42 (21–65) |
| Fibrosis assessment | |||
| By transient elastography, TE, kPa | 6.3 (5.3–8.3) | 5.6 (5.3–7.9) | 5.2 (4.6–7.7) |
| TE, Fibrosis grade, % (n) | |||
| F0–F1 | 46.2 (18) | 55.5 (10) | 61.1 (11) |
| F2 | 35.9 (14) | 16.7 (3) | 16.7 (3) |
| F3 | 10.3 (4) | 16.7 (3) | 22.2 (4) |
| F4 | 7.7 (3) | 11.1 (2) | 0.0 (0) |
| Liver biopsy fibrosis grade (Metavir), % (n) | |||
| F0 | 61.5 (24) | 61.1 (11) | 83.3 (15) |
| F1 | 30.8 (12) | 33.3 (6) | 16.7 (3) |
| F2 | 0.0 (0) | 0.0 (0) | 0.0 (0) |
| F3 | 7.7 (3) | 5.6 (1) | 0.0 (0) |
| F4 | 0 (0) | 0.0 (0) | 0.0 (0) |
All values are presented as median (25th–75th percentiles) except where specified.
HBeAg = HB “e” antigen; HBsAg = HB surface antigen; qHBsAg = quantitative HBsAg; NA = not applicable.
a
Original cohort described in Singh et al.61 Demographic details of the current substudy are included at enrolment (prior to ART) and after at least 2 years on suppressive ART (on ART).